Results 301 to 310 of about 47,580 (341)

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders. [PDF]

Blood Adv
Serna Á, Navarro V, Jiménez M, Iraola-Truchuelo J, Bosch M, García C, Falcó A, Albasanz A, Ruiz-Camps I, Andrés C, Antón A, Esperalba J, Ferrero A, García T, Carpio C, Crespo M, Iacoboni G, Marín-Niebla A, Bosch F, Abrisqueta P.   +19 more
europepmc   +1 more source

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. [PDF]

Front Immunol
Chen L, Zhu Y, Feng M, Zuo D, Chen G, Ji K.   +5 more
europepmc   +1 more source

Supplementary Figure S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao, Yongsheng Wang, Wei Hong, Yan Huang, Yunpeng Yang, Wenfeng Fang, Shaodong Hong, Yang Zhang, Qianwen Liu, Yi Zhu, Hai Zhu, Sa Xiao, Li Zhang, Hongyun Zhao   +15 more
openalex   +1 more source

A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. [PDF]

Nat Med
Liu C, Liu D, Ji Y, Sun M, Gao S, Ma X, Zhong D, Zhu J, Cao Y, Qi C, Zhang M, Zhang P, Xue R, Peng Z, Zhou J, Ge S, Lu M, Yuan J, Wang Y, Wang Z, Li J, Zhang X, Zhu Y, Zhu H, Xiao S, Gong J, Shen L, Lu Z.   +27 more
europepmc   +1 more source

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors. [PDF]

Exp Hematol Oncol
Liu R, Lin R, Li N, Li G, Zhang T, Zhao J, Li J, Sun M, Wang K, An H, Zhang W, Xu H, Zeng S, Zhang M, Duan W, Bai Y, Zhang J, Tian H, Yin F, Kang Y, Xu Q, Xu N, Deng Y, Chen Q, Li Y, Yang H, Su F, Xiao Z, Xiang X, Zhou P, Huang S, Zhang J, Xu J.   +32 more
europepmc   +1 more source

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.

Blood
Tumuluru S, Godfrey JK, Cooper A, Yu J, Chen X, MacNabb BW, Venkataraman G, Zha Y, Pelzer B, Song J, Duns G, Sworder BJ, Raj S, Bolen C, Penuel E, Postovalova E, Kotlov N, Bagaev A, Fowler N, Shouval R, Smith SM, Alizadeh AA, Steidl C, Kline J.   +23 more
europepmc   +1 more source

Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney disease

Promruk W, Jayash S, Chutoe C, Ke HZ, Liu X, von Kriegsheim A, Cawthorn W, Staines K, Stephen L, Farquharson C.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire   +2 more sources

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +2 more sources